NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.04 +0.04 (+0.05%) GOLD FUTURES
2,312.40 +1.40 (+0.06%) DOW
38,159.73 +256.44 (+0.68%) Bitcoin GBP
47,184.81 +1,475.59 (+3.23%)
ARCA biopharma, Inc. (ABIO)
| Previous close | 3.2500 |
| Open | 3.3500 |
| Bid | 3.2200 x 100 |
| Ask | 3.2500 x 200 |
| Day's range | 3.2002 - 3.3500 |
| 52-week range | 1.5600 - 3.8800 |
| Volume | |
| Avg. volume | 1,476,378 |
| Market cap | 46.93M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings date | 19 Jul 2024 - 23 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee o
BenzingaSmall-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details
ARCA Biopharma Inc (NASDAQ:ABIO) and Oruka Therapeutics have entered into a definitive agreement to combine the companies in an all-stock transaction. Oruka Therapeutics is a privately held biotechnology company developing novel biologics for chronic skin diseases, including plaque psoriasis. The resulting entity will focus on advancing Oruka’s pipeline, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to o
GlobeNewswireARCA biopharma and Oruka Therapeutics Announce Merger Agreement
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations thr
